TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9217687
Drug: Euglycaemia-hypoglycaemia-euglycaemia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia-hypoglycaemia-euglycaemia treatment order
Study: 9217687
Drug: Euglycaemia-placebo(euglycaemia)-euglycaemia treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia-placebo(euglycaemia)-euglycaemia treatment sequence
Study: 973963
Drug: Diazepam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (2.5 mg)
Study: 973963
Drug: Amylobarbitone sodium
Normalized name: Amylobarbitone sodium
DrugBank: Amobarbital (DB01351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amylobarbitone sodium (50 mg)
Study: 977791
Drug: Amylobarbitone sodium
Normalized name: Amylobarbitone sodium
DrugBank: Amobarbital (DB01351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amylobarbitone sodium (100 mg)
Study: 973963
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active drugs
Study: 28830428
Drug: Synergy 1
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synergy 1 (oligofructose-enriched inulin) 10 g daily
Study: 25253582
Drug: Olmesartan combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan combined with a calcium channel blocker (CCB)
Study: 25253582
Drug: Olmesartan combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan combined with a diuretic
Study: 15385015
Drug: Fentanyl (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (30 microg x kg(‐1)) plus morphine (1 mg x kg(‐1))
Study: 9223734
Drug: Immediate zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate zidovudine (ZVD) therapy
Study: 3072419
Drug: Ketanserin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (80 mg daily)
Study: 26526507
Drug: Ribavirin (5‐10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (5‐10mg/kg daily divided into 2 doses)
Study: 21982055
Drug: Local steroids
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroids
Study: 18094011
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention focused on improving inhalation technique and medication adherence
Study: 12974594
Drug: Propofol-alfentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-alfentanil infusion
Study: 12974594
Drug: Boluses of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boluses of fentanyl with a propofol infusion
Study: 11885172
Drug: Top Performance
Normalized name: Perform Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top Performance Group (TPG) implants
Study: 11885172
Drug: Middle Performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle Performance Group (MPG) implants
Study: 11885172
Drug: Lower Performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower Performance Group (LPG) implants
Study: 11885172
Drug: HA-coated cylinder
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-coated cylinder implants
Study: 11885172
Drug: Commercially pure
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially pure titanium screw implants
Study: 1349184
Drug: Removal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removal of worms (treatment)
Study: 31500466
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin treatment
Study: 22494796
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) treatment
Study: 16496604
Drug: HA Biocer
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA Biocer implants
Study: 11868925
Drug: Corn syrup
Normalized name: Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn syrup with synthetic honey flavoring (placebo)
Study: 10520795
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug (AAD)
Study: 2656775
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg twice daily)
Study: 23617687
Drug: Multicomponent pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Multicomponent pharmaceutical care intervention (patient interview, pharmacotherapy review, execution and follow-up evaluation of a pharmaceutical care plan)
Study: 23617687
Drug: Multicomponent pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Multicomponent pharmaceutical care intervention
Study: 17526934
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day and 80 mg/day
Study: 15542205
Drug: HibCRM197 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HibCRM197 vaccine (doses > or =1.25 microg)
Study: 15542205
Drug: Hib-tetanus vaccine
Normalized name: tetanus toxoid vaccine, inactivated
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-tetanus vaccine (doses > or =1.25 microg)
Study: 11251436
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 10 mg.s-1
Study: 11251436
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 2 mg.s-1
Study: 9512842
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine 30 mg before induction of anaesthesia
Study: 9512842
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine 30 mg 20 min after skin incision
Study: 7801058
Drug: NSAID cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID cream (DOLGIT cream)
Study: 3078156
Drug: Individualized antiarrhythmic
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized antiarrhythmic therapy (mexiletine or quinidine)
Study: 3078156
Drug: Low-dose amiodarone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amiodarone (200-400 mg/day after a loading phase)
Study: 10601507
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic therapy
Study: 23887347
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiamine and cobalamin
Study: 23887347
Drug: Thiamine, Cobalamin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine, Cobalamin, Combination groups
Study: 19123324
Drug: Hallux-trampling (HT)
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hallux-trampling (HT) plus Yaotongling suppository (YS)
Study: 19123324
Drug: Hallux-trampling (HT)
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hallux-trampling (HT) plus placebo suppository
Study: 19123324
Drug: Yaotongling suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yaotongling suppository (YS) plus mock HT
Study: 17704027
Drug: Purple sweet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple sweet potato leaves (PSPLs) diet (daily consumption of 200 g PSPLs)
Study: 12602532
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (477 mg twice daily)
Study: 12602532
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (954 mg during short study)
Study: 9236628
Drug: Triple-dose Gd-DTPA
Normalized name: Gd-EOB-DTPA
DrugBank: Gadoxetic acid (DB08884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-dose Gd-DTPA (0.3 mmol/kg)
Study: 9236628
Drug: Single-dose Gd-DTPA
Normalized name: Gd-EOB-DTPA
DrugBank: Gadoxetic acid (DB08884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose Gd-DTPA with MT and short delay
Study: 9236628
Drug: Triple-dose Gd-DTPA
Normalized name: Gd-EOB-DTPA
DrugBank: Gadoxetic acid (DB08884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-dose Gd-DTPA with MT and short delay
Study: 9236628
Drug: MT imaging
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT imaging with long delay following triple-dose Gd-DTPA
Study: 8398056
Drug: Talcid suspension
Normalized name: Pulvis Talci
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talcid suspension (hydrotalcit)
Study: 21044870
Drug: GAD-alum treatment
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum treatment
Study: 19069803
Drug: Low-intensity laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity laser therapy
Study: 29874972
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no laser therapy)
Study: 26757270
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg qd + promestriene vaginal capsules intravaginally (Group A)
Study: 26757270
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg qd (Group B)
Study: 24962003
Drug: 120 mmol
Normalized name: dibasic potassium phosphate 120 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mmol l(‐1) Na(+)
Study: 24962003
Drug: 180 mmol
Normalized name: PEG-180
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mmol l(‐1) Na(+)
Study: 24962003
Drug: 60 mmol
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mmol l(‐1) Na(+)
Study: 8699333
Drug: Granulated tablet
Normalized name: Granule Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulated tablet formulation of nadolol (80 mg) - single dose
Study: 8699333
Drug: Compressed tablet
Normalized name: Ulva compressa extract
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compressed tablet formulation of nadolol (80 mg) - single dose
Study: 8699333
Drug: Granulated tablet
Normalized name: Granule Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulated tablet formulation of nadolol (80 mg) - multiple doses (once daily for 7 days)
Study: 8699333
Drug: Compressed tablet
Normalized name: Ulva compressa extract
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compressed tablet formulation of nadolol (80 mg) - multiple doses (once daily for 7 days)
Study: 1379056
Drug: Ephedrine 17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 17.5 mg and 3% Dextran 70 7.5 ml kg‐1 before delivery (group A)
Study: 1379056
Drug: Volume loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume loading with Dextran 15 ml kg‐1 without infusion of ephedrine (group B)
Study: 29938898
Drug: Venlafaxine (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (37.5 mg)
Study: 21910547
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of TOVA
Study: 21910547
Drug: Afternoon administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Afternoon administration of TOVA
Study: 20974316
Drug: Dexlansoprazole 30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole 30, 60, and 90 mg once daily
Study: 20974316
Drug: Dexlansoprazole 30
Normalized name: dexlansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole 30 or 60 mg once daily
Study: 20974316
Drug: Dexlansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole 60 and 90 mg once daily
Study: 18726104
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous gentamicin, administered 30 min before surgery.
Study: 18726104
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prophylactic antibiotics).
Study: 15652875
Drug: Repetitive TMS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Repetitive TMS (rTMS) at 5 Hz, 20 sessions (5 sessions per week) of 120% of motor threshold and 1250 pulses per session, concomitantly taking amitriptyline (mean dose 110 mg/d)
Study: 2719366
Drug: Actidose‐Aqua 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actidose‐Aqua 25 g
Study: 2719366
Drug: Super Char
Normalized name: octinoxate 7.5 mL in 100 mL / titanium dioxide 1 mL in 100 mL TOPICAL CREAM [HAVE A NICE DAY SUPER CHARGED SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super Char 25 g
Study: 53428
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B immune globulin (H.B.I.G.)
Study: 53428
Drug: Immune serum
Normalized name: IMMUNE SERUMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune serum globulin (I.S.G.)
Study: 28209175
Drug: Pressure garment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure garment therapy only
Study: 31565952
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical silicone gel and pressure garment therapy
Study: 24806033
Drug: TVR 2250
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVR 2250 mg
Study: 24806033
Drug: TVR 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVR 1500 mg
Study: 23257888
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.5% levobupivacaine injected at T10, T11, and T12 paravertebral spaces
Study: 23257888
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 0.9% NaCl solution
Study: 16572610
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg (oral preoperative dose)
Study: 16572610
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg (2 IM doses before surgery and after 12 hours)
Study: 6310241
Drug: 1,25(OH)2D3 (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25(OH)2D3 (mean dose 0.5 micrograms daily)
Study: 6310241
Drug: D3 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 (dose 100 micrograms daily)
Study: 29893182
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) delivered in group sessions once a week for eight weeks
Study: 29893182
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with citalopram (30-50 mg/day at therapeutic dosages)
Study: 22463125
Drug: 12-week intensive
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week intensive intervention of nutrition and exercise education, coping skills training and exercise (Phase I), followed by 9 months of continued monthly contact (Phase II) and then 6 months follow-up on their own.
Study: 20135645
Drug: Aspirin, Statins,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, Statins, Other NSAIDs
Study: 18084988
Drug: Modified fascia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified fascia iliaca compartment block with 30 ml 0.5% bupivacaine with 1:200,000 adrenaline, 150 microg clonidine and 9 ml 0.9% saline
Study: 18084988
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 40 ml 0.9% saline
Study: 16046714
Drug: FOS/fiber formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS/fiber formula (5.1 g/L FOS and 8.9 g/L fiber)
Study: 12404081
Drug: Caffeine (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (65 mg) consumed in de-caffeinated coffee at 1000, 1100, 1200, and 1300 hours
Study: 12404081
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg) consumed at 1300 hours
Study: 11783152
Drug: Puerarin with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puerarin with conventional treatment
Study: 7848120
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (control group after treatment)
Study: 1983346
Drug: high-dose H2-blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose H2-blockade with ranitidine 300 mg q.d.s.
Study: 1983346
Drug: high-dose H2-blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose H2-blockade with ranitidine 1200 mg o.m.
Study: 1983346
Drug: high-dose H2-blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose H2-blockade with sufotidine 600 mg b.d.
Study: 23049928
Drug: Weekly text
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly text message support intervention
Study: 20948256
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with S‐1 (more than 50% of the total scheduled dose)
Study: 20948256
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with S‐1 (less than 50% of the total scheduled dose)
Study: 17635756
Drug: Intensive multiple
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multiple risk factor modification (targeting hypercholesterolaemia, hyperhomocysteinaemia, anaemia and disordered bone mineral metabolism)
Study: 7547855
Drug: Liquid fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid fibre (LF) 300 ml
Study: 2127790
Drug: Recombinant alpha‐interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha‐interferon (5 mega units thrice weekly for 2 months, then 1.5 mega units until the eighteenth month)
Study: 25852206
Drug: EPA+DHA (3.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA (3.9 g/day)
Study: 23298459
Drug: Instructional sets
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Instructional sets emphasizing concussion history or gender (specifics on dosage and duration not available)
Study: 23298459
Drug: Gender stereotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender stereotype condition (specifics on dosage and duration not available)
Study: 15172862
Drug: Intrauterine lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine lidocaine (3 mL of buffered 2% lidocaine solution)
Study: 9578059
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with autologous stem cell support
Study: 9928572
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose treatment
Study: 7830545
Drug: Degni‐Cordeiro's microsurgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degni‐Cordeiro's microsurgical indirect lymphatico‐venous shunt (L.V.S.) surgery
Study: 29284183
Drug: Peanut oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oral food challenge (OFC)
Study: 28933961
Drug: 17β-Estradiol (E2),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17β-Estradiol (E2), 0.72 mg transdermally for 2-8 weeks
Study: 28933961
Drug: 17β-Estradiol (E2),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17β-Estradiol (E2), 0.62 mg and norethindrone acetate (P), 2.70 mg for 3-16 weeks
Study: 28933961
Drug: Estra-1,3,5(10)-triene-3,16α, 17β-triol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estra-1,3,5(10)-triene-3,16α, 17β-triol (E3) vaginal tablet 0.5 mg per month five times
Study: 21592309
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (30 mg)
Study: 18440921
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (15 mg)
Study: 16529577
Drug: Testogel (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testogel (5 g containing 50 mg testosterone, daily) for 4 weeks, followed by tadalafil (20 mg, twice a week)
Study: 16529577
Drug: Testogel (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testogel (5 g containing 50 mg testosterone, daily) for 10 weeks before adjunctive therapy with tadalafil
Study: 16529577
Drug: Testogel and
Normalized name: Testopel
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testogel and tadalafil combination therapy
Study: 9236443
Drug: Dual-chamber rate-responsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-chamber rate-responsive pacemaker therapy
Study: 7958108
Drug: ELISA for
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA for insulin antibodies (IA) in IDDM patients
Study: 7958108
Drug: ELISA for
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA for insulin antibodies (IA) in NIDDM patients treated with insulin
Study: 7958108
Drug: ELISA for
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA for insulin autoantibodies (IAA) in NIDDM patients without insulin therapy
Study: 7958108
Drug: ELISA for
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA for insulin autoantibodies (IAA) in Graves' disease patients
Study: 7958108
Drug: RBA for
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBA for insulin autoantibodies (IAA) in NIDDM patients without insulin therapy
Study: 7958108
Drug: RBA for
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBA for insulin autoantibodies (IAA) in Graves' disease patients
Study: 3309444
Drug: 3% Acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Acyclovir eye ointment
Study: 3309444
Drug: 3% Adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Adenosine Arabinoside eye ointment
Study: 23276775
Drug: Guided intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided intervention (10 session workbook, 10 biweekly, 8 monthly, and 6 bimonthly phone coaching calls, bimonthly weight graphs, tailored letters)
Study: 19956091
Drug: Hemin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemin (3 mg/kg intravenously in 25% albumin)